Chester County News and Community Website
WILMINGTON, DE — CSC has once again secured top recognition in the New York Law Journal’s annual “Best Of” survey, earning high rankings in two key categories.
CSC Earns Top Honors in New York Law Journal’s “Best Of” Survey Read More
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to their supplemental Biologics License Application (sBLA) for …
FDA Grants Priority Review for ENHERTU Combo in Advanced Breast Cancer Read More WILMINGTON, DE — A new international study by CSC shows strong investor momentum toward private credit, with 82% of limited partners (LPs) expecting to increase allocations over the next three …
CSC Study Finds 82% of Investors Plan to Boost Private Credit Allocations Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) has appointed Dave Gardner as Executive Vice President and Chief Strategy Officer. Gardner will join the company’s Executive Leadership Team, overseeing corporate strategy and …
Incyte Names Dave Gardner Chief Strategy Officer Amid Leadership Transition Read More
WILMINGTON, DE — Diversified LLC is honored to announce that it has been recognized by Forbes as one of America’s Top Registered Investment Advisory Firms for 2025. This prestigious recognition …
Diversified LLC Named to Forbes’ 2025 List of America’s Top RIA Firms Read More
WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced it has received U.S. Food and Drug Administration (FDA) approval of a Suitability Petition allowing the company to proceed with its …
NRx Wins FDA Nod to Advance Preservative-Free Ketamine Product KETAFREE Read More
WILMINGTON, DE — Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW; OTC: ONFOP) announced its Board of Directors has declared a regular quarterly dividend of $0.75 per share on the company’s outstanding …
Onfolio Declares Quarterly Dividend on Series A Preferred Stock Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration has approved Opzelura (ruxolitinib) cream 1.5% for children as young as two with mild to moderate …
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis Read More WILMINGTON, DE — The U.S. prescribing information for AIRSUPRA now includes results from the Phase IIIb BATURA trial, which demonstrated that the medication significantly reduced severe asthma exacerbations in patients …
AIRSUPRA Label Expanded With Evidence of Risk Reduction in Mild Asthma Read More
WILMINGTON, DE — EnterpriseDB (EDB) released new global research showing that most enterprises are struggling to scale agentic and generative AI, with 87% at risk of falling behind due to …
EnterpriseDB Report Warns 87% of Enterprises Risk Falling Behind in AI Race Read More